Peter Seufer-Wasserthal
Plus aucun poste en cours
Fortune : 31 667 $ au 31/03/2024
Profil
Peter Seufer-Wasserthal held several positions in various companies, including Director at Willow Biosciences, VP & General Manager-Pharma Services at Codexis, and Vice President-Business Development at Precigen, Morphochem AG, and Altus Pharmaceuticals.
He also served as Principal at Evotec SE and Oxford Asymmetry International Plc.
He earned a doctorate degree from Graz University of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
WILLOW BIOSCIENCES INC.
0,34% | 28/04/2023 | 416 665 ( 0,34% ) | 31 667 $ | 31/03/2024 |
Anciens postes connus de Peter Seufer-Wasserthal
| Sociétés | Poste | Fin |
|---|---|---|
| WILLOW BIOSCIENCES INC. | Chief Executive Officer | 28/03/2023 |
Sestina Bio LLC
 Sestina Bio LLC Packaged SoftwareTechnology Services Sestina Bio LLC operates a platform for automated synthetic biology. It provides technology centric, R&D platform to provide cutting edge solutions to sustainably feed and clothe. The firms approach is to integrate tools for genome editing, single cell biology, and machine learning to transform ability to engineer and harness biological function. The company was founded by William Wayne Colston, Jr. and is headquartered in Pleasanton, CA. | Corporate Officer/Principal | 01/08/2022 |
origenis GmbH
 origenis GmbH Packaged SoftwareTechnology Services Origenis GmbH is a German biopharmaceutical company that specializes in developing small molecule medicines and diagnostics for neurodegenerative and neuroinflammatory diseases. The private company is based in Martinsried, Germany. The company's unique capabilities in drug design, compound synthesis, and characterization allow them to engineer a continuous stream of proprietary intellectual property (IP)-protected new chemical entities capable of permeating the blood-brain barrier. Origenis has a significant IP and R&D portfolio that ensures strong patent protection. Origenis was founded in 2005, and the CEO is Michael Almstetter. | Corporate Officer/Principal | 01/12/2020 |
| PRECIGEN, INC. | Corporate Officer/Principal | 01/02/2018 |
Altus Pharmaceuticals, Inc.
 Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | Corporate Officer/Principal | - |
Formation de Peter Seufer-Wasserthal
| Graz University of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| CODEXIS, INC. | Process Industries |
| PRECIGEN, INC. | Health Technology |
| EVOTEC SE | Health Technology |
| WILLOW BIOSCIENCES INC. | Commercial Services |
| Entreprise privées | 5 |
|---|---|
| Oxford Asymmetry International Plc | Process Industries |
Morphochem AG
 Morphochem AG Miscellaneous Commercial ServicesCommercial Services Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany. | Commercial Services |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | Health Technology |
origenis GmbH
origenis GmbH Packaged SoftwareTechnology Services Origenis GmbH is a German biopharmaceutical company that specializes in developing small molecule medicines and diagnostics for neurodegenerative and neuroinflammatory diseases. The private company is based in Martinsried, Germany. The company's unique capabilities in drug design, compound synthesis, and characterization allow them to engineer a continuous stream of proprietary intellectual property (IP)-protected new chemical entities capable of permeating the blood-brain barrier. Origenis has a significant IP and R&D portfolio that ensures strong patent protection. Origenis was founded in 2005, and the CEO is Michael Almstetter. | Technology Services |
Sestina Bio LLC
Sestina Bio LLC Packaged SoftwareTechnology Services Sestina Bio LLC operates a platform for automated synthetic biology. It provides technology centric, R&D platform to provide cutting edge solutions to sustainably feed and clothe. The firms approach is to integrate tools for genome editing, single cell biology, and machine learning to transform ability to engineer and harness biological function. The company was founded by William Wayne Colston, Jr. and is headquartered in Pleasanton, CA. | Technology Services |
